STA
VKTX icon

Summit Trail Advisors’s Viking Therapeutics VKTX Stock Holding History

Summit Trail Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$577K Buy
17,746
+2,552
+17% +$82K 0.01% 1119
2025
Q4 		$535K Buy
+15,194
New +$538K 0.01% 1054

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Summit Trail Advisors's VKTX Position: Q1 2026 in Review

Summit Trail Advisors increased its Viking Therapeutics (VKTX) stake by 17% in Q1 2026, buying an estimated $82K and bringing the position to 17,746 shares worth $577K. The position accounts for 0.01% of the portfolio, ranked #1119.

Summit Trail Advisors first reported a position in VKTX in Q4 2025 and has held it in 2 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Summit Trail Advisors held 17,746 shares of Viking Therapeutics worth $577K as of Q1 2026.
  • Summit Trail Advisors bought 2,552 Viking Therapeutics shares in Q1 2026, an estimated $82K.
  • Viking Therapeutics made up 0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1119 holding.
  • Summit Trail Advisors first reported a position in Viking Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.